The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Clutton, G ^a   Xu, Y ^a   Baldoni, P L ^b   Mollan, K R ^c   Kirchherr, J ^a   Newhard, W ^d   Cox, Kara ^d   Kuruc, J D ^a   Kashuba, A ^e   Barnard, R ^d   Archin, N ^a   Gay, C L ^a   Hudgens, M G ^b   Margolis, D M ^a   Goonetilleke, N ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; PANOBINOSTAT; PROTEIN KINASE INHIBITOR; VORINOSTAT;

ADULT; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; INDOLES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 84982683043     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30749     Document Type: Article

References (60)

1. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25, 207-212, doi: 10. 1089/aid. 2008. 0191 (2009).
2. Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends in microbiology 21, 277-285, doi: 10. 1016/j. Tim. 2013. 02. 005 (2013).
3. Jiang, G. et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 28, 1555-1566, doi: 10. 1097/QAD. 0000000000000289 (2014).
4. Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. Plos One 5, e11160, doi: 10. 1371/journal. pone. 0011160 (2010).
5. Williams, S. A. et al. Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279, 42008-42017, doi: 10. 1074/jbc. M402124200 (2004).
6. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485, doi: 10. 1038/nature11286 [pii] (2012).
7. Elliott, J. H. et al. Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. Plos Pathog 10, e1004473, doi: 10. 1371/journal. ppat. 1004473 (2014).
8. Sogaard, O. S. et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. Plos Pathog 11, e1005142, doi: 10. 1371/journal. ppat. 1005142 (2015).
9. Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1/2, single group, clinical trial. The lancet. HIV 1, e13-21, doi: 10. 1016/S2352-3018(14)70014-1 (2014).
10. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501, doi: 10. 1016/j. immuni. 2012. 01. 014 (2012).
11. Sung, J. A. et al. Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. J Infect Dis, doi: 10. 1093/infdis/jiv022 (2015).
12. Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385, doi: 10. 1038/nature14053 (2015).
13. Akimova, T., Beier, U. H., Liu, Y., Wang, L. & Hancock, W. W. Histone/protein deacetylases and T-cell immune responses. Blood 119, 2443-2451, doi: 10. 1182/blood-2011-10-292003 (2012).
14. Biancotto, A. et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78, 10507-10515, doi: 10. 1128/JVI. 78. 19. 10507-10515. 2004 (2004).
15. Hess, A. D., Silanskis, M. K., Esa, A. H., Pettit, G. R. & May, W. S. Activation of human T lymphocytes by bryostatin. J Immunol 141, 3263-3269 (1988).
16. Ariza, M. E. et al. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J Biol Chem 286, 24-34, doi: 10. 1074/jbc. M110. 135921 (2011).
17. Jones, R. B. et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. Plos Pathog 10, e1004287, doi: 10. 1371/journal. ppat. 1004287 (2014).
18. Laird, G. M. et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest, doi: 10. 1172/ JCI80142 (2015).
19. Korin, Y. D., Brooks, D. G., Brown, S., Korotzer, A. & Zack, J. A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76, 8118-8123 (2002).
20. Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T cell activation. Annu Rev Immunol 27, 591-619, doi: 10. 1146/annurev. immunol. 021908. 132706 (2009).
21. Clive, S. et al. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer chemotherapy and pharmacology 70, 513-522, doi: 10. 1007/ s00280-012-1940-9 (2012).
22. Iwamoto, M. et al. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer chemotherapy and pharmacology 72, 493-508, doi: 10. 1007/s00280-013-2220-z (2013).
23. Woo, S. et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clinical cancer research: An official journal of the American Association for Cancer Research 15, 1496-1503, doi: 10. 1158/1078-0432. CCR-08-1215 (2009).
24. Sharma, S. et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer chemotherapy and pharmacology 75, 87-95, doi: 10. 1007/ s00280-014-2612-8 (2015).
25. Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. Plos Pathog 10, e1004071, doi: 10. 1371/journal. ppat. 1004071 (2014).
26. Spivak, A. M. et al. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients. Antimicrob Agents Chemother, doi: 10. 1128/AAC. 01077-15 (2015).
27. Pavlick, A. C. et al. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory nonhematologic tumors. Cancer chemotherapy and pharmacology 64, 803-810, doi: 10. 1007/s00280-009-0931-y (2009).
28. Saleh, S. et al. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology 8, 80, doi: 10. 1186/1742-4690-8-80 (2011).
29. Acuto, O., Di Bartolo, V. & Michel, F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol 8, 699-712, doi: 10. 1038/nri2397 (2008).
30. Peters, P. J. et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 173, 1099-1109 (1991).
31. Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281, 65-78 (2003).
32. Takada, Y., Gillenwater, A., Ichikawa, H. & Aggarwal, B. B. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281, 5612-5622, doi: 10. 1074/jbc. M507213200 (2006).
33. Uchida, H. et al. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through upregulation of glycodelin. Endocrinology 148, 896-902, doi: 10. 1210/en. 2006-0896 (2007).
34. Lin, K. T. et al. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clinical cancer research: An official journal of the American Association for Cancer Research 18, 4691-4701, doi: 10. 1158/1078-0432. CCR-12-0633 (2012).
35. Jonsson, K. L. et al. Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob Agents Chemother 59, 3984-3994, doi: 10. 1128/AAC. 00574-15 (2015).
36. Gutierrez, C. et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy: A phase i, doubleblind clinical trial. AIDS, doi: 10. 1097/QAD. 0000000000001064 (2016).
37. Bosco, M. C. et al. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Blood 89, 3402-3411 (1997).
38. Curiel, R. E., Garcia, C. S., Farooq, L., Aguero, M. F. & Espinoza-Delgado, I. Bryostatin-1 and IL-2 synergize to induce IFN-gamma expression in human peripheral blood T cells: implications for cancer immunotherapy. J Immunol 167, 4828-4837 (2001).
39. Black, J. D. Protein kinase C-mediated regulation of the cell cycle. Frontiers in bioscience: A journal and virtual library 5, D406-423 (2000).
40. Nelson, T. J. & Alkon, D. L. Neuroprotective versus tumorigenic protein kinase C activators. Trends in biochemical sciences 34, 136-145, doi: 10. 1016/j. Tibs. 2008. 11. 006 (2009).
41. Plimack, E. R. et al. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The oncologist 19, 354-355, doi: 10. 1634/theoncologist. 2014-0020 (2014).
42. Lam, A. P. et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. American journal of clinical oncology 33, 121-124, doi: 10. 1097/COC. 0b013e3181a31920 (2010).
43. Barr, P. M. et al. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. American journal of hematology 84, 484-487, doi: 10. 1002/ajh. 21449 (2009).
44. van Sighem, A. I. et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24, 1527-1535, doi: 10. 1097/QAD. 0b013e32833a3946 (2010).
45. Burnett, J. C. et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 84, 5958-5974, doi: 10. 1128/ JVI. 00161-10 (2010).
46. Reuse, S. et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. Plos One 4, e6093, doi: 10. 1371/journal. pone. 0006093 (2009).
47. Martinez-Bonet, M. et al. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Scientific reports 5, 16445, doi: 10. 1038/srep16445 (2015).
48. DeChristopher, B. A. et al. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nature chemistry 4, 705-710, doi: 10. 1038/nchem. 1395 (2012).
49. Beans, E. J. et al. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci USA 110, 11698-11703, doi: 10. 1073/pnas. 1302634110 (2013).
50. Marsden, M. D. In HIV Persistence During Therapy Seventh International Workshop.
51. Trushin, S. A. et al. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol 79, 9821-9830, doi: 10. 1128/JVI. 79. 15. 9821-9830. 2005 (2005).
52. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29, 255-265, doi: 10. 1038/nbt. 1759 (2011).
53. Spina, C. A. et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. Plos Pathog 9, e1003834, doi: 10. 1371/journal. ppat. 1003834 (2013).
54. Choi, S. H., Hyman, T. & Blumberg, P. M. Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase Cdelta. Cancer Res 66, 7261-7269, doi: 10. 1158/0008-5472. CAN-05-4177 (2006).
55. Oh, J. G. et al. Biphasic Effects of Ingenol 3, 20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses. Molecular pharmacology 88, 392-400, doi: 10. 1124/mol. 114. 097436 (2015).
56. Olesen, R. et al. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol, doi: 10. 1128/JVI. 01484-15 (2015).
57. Campbell, G. R., Bruckman, R. S., Chu, Y. L. & Spector, S. A. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem 290, 5028-5040, doi: 10. 1074/jbc. M114. 605428 (2015).
58. Archin, N. M. et al. HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat. J Infect Dis 210, 728-735, doi: 10. 1093/infdis/jiu155 (2014).
59. Hezareh, M. et al. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antiviral chemistry & chemotherapy 15, 207-222 (2004).
60. Currier, J. R. et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260, 157-172 (2002).